Source: Eye Future; Editor: Seven KiteReprint requirements: Can be reprinted 24 hours after the first publication, source must be credited.
Recently,Beijing Zhizhen Health Technology Co., Ltd. (ZHENHEALTH®️)Official ReleaseThe World's First：Da Vinci·AI Ophthalmology Medical Imaging Auxiliary Diagnosis All-in-One Machine。The Da Vinci·AI Ophthalmology Medical Imaging Assisted Diagnosis All-in-One Machine integrates various intelligent algorithms, enabling more efficient and accurate assistance for doctors in completing diagnostic tasks.Significantly Improve Clinical Diagnostic Efficiency, effectively empowering clinical applications. This workstation can be widely used in various clinical departments such as ophthalmology, physical examination, diabetes specialty, endocrinology, geriatrics, obstetrics and gynecology, and neurology.Currently, the algorithm built into the workstationApproved NMPA AI Class III certificate and multiple NMPA Class II certificates。# Overview of the Ophthalmology AI MarketAccording to a report by Global Market Insights, the compound annual growth rate of the global medical AI market size will exceed 29%.It will reach 70 billion US dollars in 2032According to the Frost & Sullivan report, from 2022 to 2032,The market size of China's medical artificial intelligence industry is expected to increase from 6.8 billion yuan to 311 billion yuan., with a high compound annual growth rate of 46.6%.More than 90% of the data in ophthalmic medical data comes from medical imaging., but the diagnosis of medical images relies on artificial subjective analysis. Artificial analysis can only judge based on experience, which is prone to misjudgment. According to data from the Chinese Medical Association,The number of misdiagnosed patients in China's clinical medical care each year is approximately 57 million, with a total misdiagnosis rate of 27.8%.. For pathologists, it is difficult to rely on experience to find tiny lesions among numerous small ocular structures, and misdiagnosis occurs from time to time.The emergence of artificial intelligence technology has alleviated the above problems to a certain extent.. UtilizeImage Recognition TechnologyBy extensively studying medical images, AI-assisted diagnostic products can help doctors locate lesion areas, effectively reducing the problems of missed diagnoses and misdiagnoses.The integration of AI and ophthalmology has led to deeper advancements in the screening, diagnosis, and prognosis of eye diseases.In view of the large amount of clinical data and multimodal imaging generated on-site,Ophthalmology AI can increase patients' access to clinical screening and diagnosis while reducing healthcare costs., especially when applied in high-risk populations, resource-poor communities, or in conjunction with telemedicine programs, the advantages of ophthalmic AI become more prominent.From auxiliary diagnosis of diabetic retinopathy syndrome to auxiliary screening of cardiovascular diseases and one-stop solutions for eye health,Multiple companies are continuously validating the feasibility of AI commercialization.。From the expansion of AI technology application scenarios, we can clearly seeLogical Main Line, that is,Improving Efficiency with AI-Assisted Diagnosis, assist community health centers in completing the preliminary screening of a series of high-incidence chronic diseases in China in scenarios with insufficient medical resources.Moreover, with the continuous advancement of technology and the ongoing capital injection, more attention is being paid to whether ophthalmic AI companies can successfully implement and establish a stable business model. Currently, artificial intelligence medical imaging products are mainly used in the disease screening stage, making it a field with relatively high commercialization difficulty. However,AI Medical Imaging is Most Likely to Achieve Commercialization First in All Sub-Segments。
▲Differences in Business Models Among Enterprises (Originated fromHongyi CapitalThe Da Vinci·AI Ophthalmology Medical Imaging Auxiliary Diagnosis All-in-One Machine integrates multiple intelligent algorithms, which can assist doctors in completing diagnostic tasks more efficiently and accurately, greatly improving clinical diagnostic efficiency and effectively empowering clinical practice.This means completing multiple inspection and treatment tasks on a single platform, without the need to frequently switch devices or systems. This willSignificantly improve work efficiency while reducing operating costs。It also addresses many issues in traditional screening processes, such as complicated testing and lack of synchronized information.. In addition, the introduction of artificial intelligence has madeNon-ophthalmologists can also participate in early screening for eye health among various populations.With this technology, it is possible to more effectively monitor eye diseases and their complications caused by chronic conditions, aging, and other factors, providing patients with more timely and precise health protection.
The workstation not only hasPowerful Data Integration Capability, which can efficiently collect and organize multimodal imaging data generated by different medical devices, also hasExcellent data analysis capabilities, which allows for in-depth mining and analysis of this data, revealing the potential patterns and characteristics of eye diseases.The workstation alsoCompatible with multi-brand, multi-vendor equipment from upstream supply chain, throughAI Technology Deeply Integrated Equipment, providing full-process empowerment for data transmission, processing, integration, and analysis, thereby ensuring the efficiency, continuity, and stability of medical services.
Beijing Zhizhen Health Technology Co., Ltd.(ZHENHEALTH®️) was established in Haidian, Beijing in 2015, and is committed to providing high-quality services/products for the healthcare industry.Artificial Intelligence Health Management Solutions。
The core team comes from the world's top academic research institutions and Fortune 500 high-tech companies. With years of deep accumulation in technologies such as artificial intelligence, cloud computing, and big data, as well as a new operational model for health management, they efficiently integrate high-quality medical service resources both in China and internationally.Achieve the interconnection of users, pharmaceutical services and clinical technology。
Zhizhen Health's services focus onEarly Screening, Quantitative Assessment, and Auxiliary Diagnosis for National Health. The R&D production line covers the health management needs throughout the entire human life cycle,A number of self-developed software and hardware products have obtained Class III and Class II medical device registration certificates issued by the China Food and Drug Administration., with nearly a hundred global patents, has completed medical device approvals from the US FDA and EU CE.
As of the date of publication, the company's financing history is as follows:
